🇺🇸 FDA
Patent

US 11377502

Anti-MSR1 antibodies and methods of use thereof

granted A61KA61K2039/505A61K31/165

Quick answer

US patent 11377502 (Anti-MSR1 antibodies and methods of use thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2039/505, A61K31/165, A61K31/167, A61K31/417